Initiation of salvage therapy for prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 2, 2002, Pages 136-143

  Johnstone, P A S ^a,b   Booth, R ^a   Riffenburgh, R H ^a   Amling, C L ^a   Kane, C J ^a   Moul, J W ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Center for Prostate Disease Research   (United States)

Author keywords

Follow up care; Prostatic neoplasma; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CLINICAL PRACTICE; DECISION MAKING; EPIDEMIOLOGY; HUMAN; MALE; MIDDLE AGED; PATIENT CARE PLANNING; PLOIDY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RISK FACTOR; SALVAGE THERAPY; STATISTICS; UROLOGY; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER GRADING; CONTROLLED STUDY; HEALTH STATUS; HEALTH SURVEY; LATENT PERIOD; LYMPH NODE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL SPECIALIST; PATIENT CARE; PERFORMANCE; PHYSICIAN; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; TREATMENT FAILURE;

ADULT; AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT CARE PLANNING; PHYSICIAN'S PRACTICE PATTERNS; PLOIDIES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SALVAGE THERAPY; UROLOGY; HUMAN; MIDDLE AGE;

EID: 0035996411     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500566     Document Type: Article

References (13)

1. Therapy of early progression of prostate cancer
2. Prostate specific antigen only progression of prostate cancer
3. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results
4. Natural history of progression after PSA elevation following radical prostatectomy
5. Therapeutic radiation in patients with a rising post-prostatectomy PSA level
6. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy
7. The management of PSA failure after radical radiotherapy for localized prostate cancer
8. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer
9. Treatment of advanced prostate cancer
10. Update results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
11. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs, short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy
12. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial
13. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer